Brenus Pharma announces its international Scientific Committee
7.6.2023 19:00:00 EEST | Business Wire | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.
The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:
Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board
Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active member. Expertise in new drugs development.
Pr Alexander EGGERMONT MD, PhD. Pr of Oncology – Head of Clinical & Translational Immunotherapies. UMC 4, Utrecht (NL); Chief Scientific Officer. Pediatric oncology center Princessa Maxima, Utrecht. (NL)
Pr. Antoine ITALIANO MD, PhD. Pr of Oncology – Head of Early-phase trials units; Head of Precision medicine new program. Gustave Roussy, Cancer Campus Grand Paris (FR) ; Bergnonié Institute, UNICANCER Nouvelle-Aquitaine, Bordeaux. (FR)
Pr. Ignacio MELERO MD, PhD. Pr of Immunology – Head of translational immunotherapy research. CIMA 5, Navarra. (SP)
Pr Marck YARCHOAN MD. Associate Pr. of Medical Oncology at The Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins, Baltimore. (USA)
“Brenus is honored to have support & guidance of such professionals in the field. Their expertise will be instrumental in driving the first-in-human study forward and advancing the company’s mission to change a paradigm in oncology.” Benoit PINTEUR, Co-founder & CSO.
ABOUT BRENUS
Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.
For further information: www.brenus-pharma.com
____________________________
1 « Efficacy of STC-1010, a new allogeneic cancer vaccine in colorectal cancer models”
J Clin Oncol 41, 2023 (suppl 16; abstr e14661).
2 Centre de lutte contre le cancer Georges François Lecrec
3 European Society for Medical Oncology
4 University MC
5 Centro de Investigation Medical Aplicada
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005688/en/
Contact information
CONTACT BRENUS
Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership26.2.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025. “These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA has firmly established itself as the global leader in the BTK inhibitor class, distinguished by broad regulatory approvals, expanding geographic reach, strong physician adoption, and unmatched long-term efficacy and safety data in CLL. At the same time, we are securing new indications and expanded reimbursement for TEVIMBRA across key markets worldwide. With our late-stage, foundational hematology assets nearing commercialization and a robust solid tumo
Cyviz Unveils Containerized C2 Solution During HEIMDALL26.2.2026 12:00:00 EET | Press release
During Exercise HEIMDALL, organized by the Norwegian Joint Headquarters (FOH/NJHQ) this week, Cyviz is presenting its fully integrated, containerized solution for command, control, and collaboration environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226587573/en/ From deployment to operations: Cyviz’ container‑based C2 solution demonstrated during Exercise HEIMDALL. James Munt, Sales Director from Cyviz, took part in the demonstration. The solution is designed for secure, standardized, and agile operations, enabling operators to fight at the edge with assured information and supporting faster decision-making, in line with the company’s strategic focus on the defense and security sector. The container solution has been developed in collaboration with Nordic Shelter, providing the container platform. The modular platform combines control room technology, visualization, and software into one integrated system. It’s
ThreatAware Secures $25M from One Peak to Give Security Teams the Power to Build26.2.2026 12:00:00 EET | Press release
ThreatAware, the cyber asset management and cyber hygiene platform trusted by enterprises across sectors including retail, financial services, and energy, today announced it has raised $25 million in funding from One Peak, the growth equity firm specialising in high-growth software scale-ups. The investment will help ThreatAware scale its rapidly growing North American operations and accelerate its ambitious product roadmap, including the launch of ThreatAware's AI-powered security workspace. At the heart of ThreatAware's platform is its proprietary cyber asset management technology, which solves a problem most organisations don't even know they have. ThreatAware's data consistently reveals that, on average, 10% of devices accessing corporate networks go completely undetected by existing tools, while 30% of security controls are missing, misconfigured, or failing silently. As cloud adoption and remote working continue to expand the enterprise attack surface, these blind spots represent
Infobip is Set to Launch AgentOS to Orchestrate Autonomous AI-Driven Customer Journeys at Scale26.2.2026 11:00:00 EET | Press release
Global AI-first cloud communications platform Infobip, which celebrates its 20th anniversary this year, is set to launch its AI-native fully managed solution AgentOS. The new platform builds on Infobip's recently launched AI Agents, the intelligent foundation for autonomous customer communications. AgentOS is a major step in Infobip’s evolution from communications platform to intelligent orchestration layer for the AI era, enabling businesses to move from campaigns and workflows to autonomous, goal-driven interactions. AI communication models enable autonomous customer communications, hyper-personalization and highly engaging content across multiple channels. However, AI agents need a unified view of all customer touchpoints to deliver such benefits. Businesses must eliminate data silos. Yet readiness is low. Few enterprise AI agent projects reach production due to unstructured data and internal barriers. AgentOS overcomes these barriers, operationalizing AI safely and at scale across
Vonage Brings Network Innovation to Mobile World Congress 202626.2.2026 10:33:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), is set to make an impact at Mobile World Congress (MWC) 2026, the connectivity industry’s most influential exhibition, taking place March 2–5 in Barcelona. Vonage’s presence will include product demos, thought leadership sessions, and ecosystem collaborations, showcasing how the Company is leading the transformation of mobile networks into the enterprise platform of the future. “The digital arena is undergoing a fundamental shift as mobile networks transform into platforms and redefine the enterprise technology stack,” said Neelam Sandhu, Chief Marketing Officer at Vonage. “Mobile World Congress is where possibilities turn into real-world applications, and we demonstrate the capabilities and intelligence embedded in mobile networks to developers and enterprises, showcasing how they are becoming engines of innovation for industries worldwide. I am excited for Vonage to be at the helm of the thought leadership conversation and to reveal our latest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom